(Clinicaltrials.gov identifier: NCT02728401)
2013 – present: The Genotypes and Phenotypes in Pediatric SIRS and Sepsis (GAPPSS) trial is a collaborative pilot study at the Seattle Children’s Hospital between Professor Jerry Zimmerman and Immunexpress. Immunexpress and the Seattle Children’s Research Institute are jointly funding this study.
(Clinicaltrials.gov identifier: NCT02704871)
2013-present: The Ward Study for SeptiCyteTM Lab to Distinguish Between Infection-positive and Infection-negative SIRS is a non-interventional, prospective observational study to assess the performance of SeptiCyteTM Lab to diagnose patients identified as suspected of sepsis in general medical and surgical wards with infection-positive from infection-negative SIRS.
(Clinicaltrials.gov identifier: NCT02127502)
2014 – 2016: The Validation of septic gene ExpressioN Using SeptiCyte (VENUS) trial commenced in May 2014 at two Intermountain Healthcare clinical sites: the Intermountain Medical Center in Murray, UT and the Latter Day Saints hospital in Salt Lake City, UT, USA. It later expanded to five additional hospitals: Johns Hopkins Hospital in Baltimore, MD; Northwell Health in Manhasset, NY; Emory Healthcare in Atlanta GA; Loyola University Medical Center in Maywood, IL; and Rush University Medical Center in Chicago, IL. It was a prospective observational cohort study of approximately 300 ICU patients.
(Clinicaltrials.gov identifier: NCT01905033)
2011 – 2014: The MARS Sepsis Consortium trial is a prospective observational cohort study designed to produce molecular information relevant to sepsis diagnosis and management. Immunexpress is a full partner in the collaborative Consortium. The Consortium recruited 7,398 critical care patients with signs of Systemic Inflammatory Response Syndrome (SIRS) across two tertiary hospitals in the Netherlands: the Academisch Medisch Centrum in Amsterdam, and the University Medical Centre Utrecht (UMCU). Immunexpress is continuing collaborative sepsis clinical research at both study sites.
2011 – present: University College London and Immunexpress continue to collaborate in prospective observational cohort studies – Sepsis: Pathophysiological and Organizational Timing clinical trials. These longitudinal studies include septic pneumonia and immunocompromised sepsis patients.
2007 – 2011: Clinical trials across four tertiary care settings in Brisbane, Queensland (Australian New Zealand Clinical Trial Registry identified ACTRN12610000465055; Australian Department of Health and Aging CTN Number 044/2008): Wesley Hospital, Mater Health Services, Princess Alexandra Hospital and the Royal Brisbane & Women’s Hospital.